A case of desmoplastic myxoid tumor, SMARCB1 mutant, in the pineal region

2020 ◽  
Author(s):  
Yue‐E. Wang ◽  
Jing‐Jing Chen ◽  
Wei Wang ◽  
An‐Li Zhang ◽  
Wenchao Zhou ◽  
...  
Keyword(s):  
Pineal Region ◽  
Myxoid Tumor

3D Endoscope-Assisted Transtubular Approaches to the Pineal Region

2015 ◽  
Vol 76 (S 01) ◽  
Author(s):  
Antonio Bernardo ◽  
Alexander Evins ◽  
Philip Stieg
Keyword(s):  
Pineal Region ◽  
3D Endoscope

Identification of Venous Variants in the Pineal Region with 3D Preoperative Navigation. A Statistical Study on the Venous Anatomy in the Living

Skull Base ◽  
2009 ◽  
Vol 19 (01) ◽  
Author(s):  
Mario Giordano ◽  
Wolf Luedemann ◽  
Lennart Stieglitz ◽  
Karsten Wrede ◽  
Laura Columbano ◽  
...  
Keyword(s):  
Statistical Study ◽  
Pineal Region ◽  
Venous Anatomy

AJRTeaching File: Solid Masses of the Pineal Region

2006 ◽  
Vol 186 (3_supplement) ◽  
pp. S233-S235
Author(s):  
Kevin P. Banks ◽  
Stephen J. Brown
Keyword(s):  
Pineal Region

Mission impossible: chemotherapy in the intensive care for pineal region germ cell tumor

2021 ◽  
Author(s):  
Kanwaljeet Garg ◽  
Shashwat Mishra ◽  
Rahil Rafiq ◽  
KP Haresh ◽  
Manmohan Singh
Keyword(s):  
Intensive Care ◽  
Germ Cell ◽  
Germ Cell Tumor ◽  
Pineal Region ◽  
Cell Tumor

scholarly journals GCT-25. INNOVATIVE, INTENSIVE IRRADIATION-AVOIDING/MINIMIZING CHEMOTHERAPY FOR HIGH-RISK PRIMARY CENTRAL NERVOUS SYSTEM (CNS) MIXED MALIGNANT GERM CELL TUMORS (HR-MMGCT): A PILOT STUDY AND PROPOSED MULTI-NATIONAL PROSPECTIVE TRIAL

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii333-iii333
Author(s):  
Jonathan L Finlay ◽  
Mohammad H Abu-Arja ◽  
Rolla Abu-Arja ◽  
Jeffery Auletta ◽  
Mohamed S AbdelBaki ◽  
...  
Keyword(s):  
High Risk ◽  
Induction Chemotherapy ◽  
Prospective Trial ◽  
Germ Cell Tumors ◽  
Brentuximab Vedotin ◽  
Pineal Region ◽  
Chemotherapy Drugs ◽  
Molecularly Targeted Agents ◽  
Risk Patients ◽  
Intensified Chemotherapy

Abstract BACKGROUND About one-third of children with primary CNS MMGCT experience incomplete responses to initial induction chemotherapy prior to irradiation, many of whom will subsequently relapse. Such high-risk patients are variably defined as having initial alpha-fetoprotein (AFP) elevations exceeding 1,000ng/mL, predominant histopathologies of malignant non-germinomatous GCT and incomplete responses to induction chemotherapy. Drugs targeting GCT-specific molecular markers have been identified for non-germinomatous GCT elements but have yet to be incorporated into prospective clinical trials. Four children with clearly identified HR-MMGCT characteristics have been treated on an innovative pilot regimen incorporating intensified chemotherapy and molecularly targeted agents, with avoidance or minimization of irradiation. METHODS Four children (two with pure suprasellar embryonal carcinoma (EC) - one with Down syndrome and the other with pre-diagnosis cognitive dysfunction; one with initial serum AFP exceeding 7,000ng/mL and yolk sac tumor (YST)+EC+Teratoma pathology; one with initial serum AFP exceeding 1,000ng/mL) were treated with 3 cycles of “standard” induction chemotherapy (ACNS1123), followed by 1–3 transplant cycles (thiotepa/carboplatin) each with complete radiographic and tumor marker responses. Two children with pure EC subsequently received six cycles of brentuximab-vedotin without irradiation and remain disease-free off therapy for 2–4 years. One child with YST+EC+Teratoma has subsequently received reduced dose craniospinal irradiation and pineal region boost, and will receive oral everolimus, erlotinib, palbocyclib and intravenous brentuximab-vedotin. The fourth child with YST+MT will commence everolimus, erlotinib and palbocyclib without irradiation. CONCLUSION This treatment strategy for HR-MMGCT patients provides preliminary tolerance and response data justifying extension to a multi-center trial.

Sign in / Sign up

Export Citation Format

Share Document